130 related articles for article (PubMed ID: 1449724)
1. Secretion of SPARC by endothelial cells transformed by polyoma middle T oncogene inhibits the growth of normal endothelial cells in vitro.
Sage EH
Biochem Cell Biol; 1992 Jul; 70(7):579-92. PubMed ID: 1449724
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence.
Sage EH; Bassuk JA; Yost JC; Folkman MJ; Lane TF
J Cell Biochem; 1995 Jan; 57(1):127-40. PubMed ID: 7721952
[TBL] [Abstract][Full Text] [Related]
3. The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells.
Funk SE; Sage EH
Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2648-52. PubMed ID: 2011576
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts.
Funk SE; Sage EH
J Cell Physiol; 1993 Jan; 154(1):53-63. PubMed ID: 8419407
[TBL] [Abstract][Full Text] [Related]
5. Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene.
Mühlner U; Möhle-Steinlein U; Wizigmann-Voos S; Christofori G; Risau W; Wagner EF
Oncogene; 1999 Jul; 18(29):4200-10. PubMed ID: 10435633
[TBL] [Abstract][Full Text] [Related]
6. Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene.
Taraboletti G; Belotti D; Dejana E; Mantovani A; Giavazzi R
Cancer Res; 1993 Aug; 53(16):3812-6. PubMed ID: 8393382
[TBL] [Abstract][Full Text] [Related]
7. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix.
Sage H; Vernon RB; Funk SE; Everitt EA; Angello J
J Cell Biol; 1989 Jul; 109(1):341-56. PubMed ID: 2745554
[TBL] [Abstract][Full Text] [Related]
8. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment.
Williams RL; Risau W; Zerwes HG; Drexler H; Aguzzi A; Wagner EF
Cell; 1989 Jun; 57(6):1053-63. PubMed ID: 2736622
[TBL] [Abstract][Full Text] [Related]
9. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells.
Hasselaar P; Sage EH
J Cell Biochem; 1992 Jul; 49(3):272-83. PubMed ID: 1644864
[TBL] [Abstract][Full Text] [Related]
10. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1.
Lane TF; Iruela-Arispe ML; Sage EH
J Biol Chem; 1992 Aug; 267(23):16736-45. PubMed ID: 1379603
[TBL] [Abstract][Full Text] [Related]
11. Middle T antigen-transformed endothelial cells exhibit an increased activity of nitric oxide synthase.
Ghigo D; Arese M; Todde R; Vecchi A; Silvagno F; Costamagna C; Dong QG; Alessio M; Heller R; Soldi R; Trucco F; Garbarino G; Pescarmona G; Mantovani A; Bussolino F; Bosia A
J Exp Med; 1995 Jan; 181(1):9-19. PubMed ID: 7528781
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium.
Schnitzer JE; Oh P
Am J Physiol; 1992 Dec; 263(6 Pt 2):H1872-9. PubMed ID: 1481911
[TBL] [Abstract][Full Text] [Related]
13. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand.
Murphy-Ullrich JE; Lane TF; Pallero MA; Sage EH
J Cell Biochem; 1995 Feb; 57(2):341-50. PubMed ID: 7539008
[TBL] [Abstract][Full Text] [Related]
14. Murine endothelioma cell lines transformed by polyoma middle T oncogene as target for and producers of cytokines.
Bussolino F; De Rossi M; Sica A; Colotta F; Wang JM; Bocchietto E; Padura IM; Bosia A; DeJana E; Mantovani A
J Immunol; 1991 Oct; 147(7):2122-9. PubMed ID: 1918946
[TBL] [Abstract][Full Text] [Related]
15. Polyoma virus middle-T-transformed PECAM-1 deficient mouse brain endothelial cells proliferate rapidly in culture and form hemangiomas in mice.
Rothermel TA; Engelhardt B; Sheibani N
J Cell Physiol; 2005 Jan; 202(1):230-9. PubMed ID: 15389523
[TBL] [Abstract][Full Text] [Related]
16. Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta.
RayChaudhury A; Frazier WA; D'Amore PA
J Cell Sci; 1994 Jan; 107 ( Pt 1)():39-46. PubMed ID: 8175921
[TBL] [Abstract][Full Text] [Related]
17. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis.
Sage EH; Reed M; Funk SE; Truong T; Steadele M; Puolakkainen P; Maurice DH; Bassuk JA
J Biol Chem; 2003 Sep; 278(39):37849-57. PubMed ID: 12867428
[TBL] [Abstract][Full Text] [Related]
18. SPARC is a source of copper-binding peptides that stimulate angiogenesis.
Lane TF; Iruela-Arispe ML; Johnson RS; Sage EH
J Cell Biol; 1994 May; 125(4):929-43. PubMed ID: 7514608
[TBL] [Abstract][Full Text] [Related]
19. SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reduced-serum stress conditions.
Vadlamuri SV; Media J; Sankey SS; Nakeff A; Divine G; Rempel SA
Neuro Oncol; 2003 Oct; 5(4):244-54. PubMed ID: 14565160
[TBL] [Abstract][Full Text] [Related]
20. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle.
Antoine N; Greimers R; De Roanne C; Kusaka M; Heinen E; Simar LJ; Castronovo V
Cancer Res; 1994 Apr; 54(8):2073-6. PubMed ID: 7513609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
